A Phase 3 interventional study of T790M+ Testing and Baseline Visit Blood & Urine Testing in Lung Cancer, sponsored by AstraZeneca. Completed at 7 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-03-04.
Sponsored by AstraZeneca · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing osimertinib in Lung Neoplasms — 10 open to participants now, 18 under way, 2 of them phase 3. osimertinib · Lung Neoplasms.
Among the 30 studies testing osimertinib in Lung Neoplasms, this one is the 5th largest by enrollment, is one of 5 that started in 2016, is one of 4 in phase 3, and was the 11th registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →10 of the 30 studies testing osimertinib in Lung Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–99
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
Samsung Medical Center · Sites in Korea, Republic of
Ages 30–75
By country, each count listing its studies:
osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, osimertinib is the treatment under test here. Read study by study →
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 4 · Phase 4 1
First in 2014; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 256 is above the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 52 across the 30 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 30 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
63 studies in Lung Neoplasms by AstraZeneca: 12 open now, 22 under way, 3 of them phase 3. Of 39 finished, 13 (33%) have results posted.
Among the 63 studies in Lung Neoplasms by AstraZeneca, this one is the 7th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2016, is one of 9 in phase 3, and was the 28th registered.
AstraZeneca’s Lung Neoplasms studies by the year they started, since 2000.
4 of the studies testing osimertinib in Lung Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT03567642Memorial Sloan Kettering Cancer CenterA Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | 2027-06 |
| NCT02496663National Cancer Institute (NCI)Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor | 2027-06-30 |
| NCT04591002Samsung Medical CenterOsimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing osimertinib in Lung Neoplasms, from their registry updates:
Among AstraZeneca’s 63 in Lung Neoplasms:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS. And to assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy and are T790M mutation positive detected by any one of the four plasma testing platforms: Cobas/Super-ARMS/ digital PCR/NGS.
Objective: The primary objective of this study is to evaluate concordance of T790M mutation plasma testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS. And to assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR-tyrosine kinase inhibitor (TKI) therapy and are T790M mutation positive detected by any one of the four plasma testing platforms: Cobas/Super-ARMS/ digital PCR/NGS.
Study number of patients planned: Approximately 250 patients will be recruited in China.
Study Design: This is an open-label, multi-center testing and treatment study.
Target patient population: 250 locally advanced or metastatic EGFR mutation positive NSCLC patients with progression on a previous EGFR-TKI will be recruited.
Investigational product (IP), dosage, and mode of administration: AZD9291 is an oral, potent, selective, irreversible inhibitor of both EGFR-TKI sensitizing and resistance mutations in NSCLC with a significant selectivity margin over wild-type EGFR. AZD9291 will be administered orally as one 80 mg tablet once a day. All AEs/SAEs would be reported in ASTRIS main study and would not be reported repeatedly in current study.
Duration of IP administration: Patients may continue to receive AZD9291 as long as they continue to show clinical benefit, as judged by the investigator, and in the absence of discontinuation criteria. The study will be closed in a maximum period of 18 months after the last patient is enrolled. Contingencies will be made to ensure continued drug supply for patients who are still deriving benefit from AZD9291 at that time.
Study measures: Data collected will include patient demographics, smoking history, information needed to determine patient eligibility (including medical history, past and current disease characteristics, and tumor EGFR mutations status, T790M and sensitizing mutations status results and type of test performed), AZD9291 exposure, investigator-reported efficacy (including tumor response and disease progression), overall survival (OS).
Statistical methods: The concordance of T790M resistance mutation testing between the Cobas test and each of other platforms will be calculated. The sensitivity, specificity, PPV and NPV of each testing platform (Super-ARMS, digital PCR, and NGS) will be calculated with the Cobas test as the reference. The Kappa coefficient will be calculated to measure the agreement of T790M mutation testing between the Cobas test and each of other platforms. Descriptive statistics will be provided for all variables, as appropriate. Continuous variables will be summarized by the number of observations, mean, standard deviation, median, interquartile range (Q1, Q3), minimum, and maximum. Categorical variables will be summarized by frequency counts and percentages for each category. The 95% confidence interval (CI) will be calculated as appropriate. PFS and OS, respectively, will be summarized using Kaplan-Meier estimates of the median time to event (progression and death) and quartiles together with their 95% confidence intervals.The chi-square test will be used to compare the sensitivity, specificity, and concordance between any of the two platforms using Cobas as reference testing in an exploratory manner.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm of AZD9291, starting dose of 80mg
Procedure: T790M+ Testing · Procedure: Baseline Visit Blood & Urine Testing · Procedure: Baseline ECG · Procedure: Visual Slit-Lamp Testing · Drug: AZD9291 Dosing · Procedure: Plasma AZD9291 testing
The patient will need to have T790M+ testing
Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
ECG to ensure absence of any cardiac abnormality
Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
The patient will need to have plasma AZD9291 testing before treatment
Concordance
To evaluate concordance of T790M plasma mutation testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.
Time frame: Up to 6 months
PFS Using Investigator Assessments According to RECIST v1.1
To assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR- TKI therapy and are T790M mutation positive detected by any one of the four plasma testing platforms. PFS was defined using Response Evaluation Criteria In Solid Tumors version 1.1(RECIST v1.1).
Time frame: The time from first dose of AZD9291 in this study until the date of disease progression as recorded in CRF or death (by any cause in the absence of progression), assessed up to 18 months
Testing Sensitivity, Specificity, PPV, NPV
To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Super-ARMS/digital PCR/NGS by using Cobas as the reference.
Time frame: Up to 6 months.
Overall Response Rate (ORR)
To assess the efficacy of AZD9291 monotherapy by assessment of ORR in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. ORR is defined as the percentage of patients with measurable disease with at least 1 visit response of CR or PR. Data obtained until progression or last evaluable assessment in the absence of progression will be included in the assessment of ORR.
Time frame: From first patient first CT scan for RECIST assessment, till the last patient last CT scan, up to 22 months.
75% OS Duration
To assess the efficacy of AZD9291 monotherapy by assessment of overall survival (OS) in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. 75% OS duration was calculated.
Time frame: From first patient signed the consent to study completion, up to 22 months.
1. Provision of informed consent prior to any study specific procedures. 2. Adults (according to China regulations for age of majority). 3. Histological or cytological confirmed locally advanced NSCLC (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy. 4. Patients who have progressed following prior therapy with an EGFR-TKI agent.
| Milestone | Experimental |
|---|---|
| Started | 256 |
| Completed | 256 |
| Not completed | 0 |
To evaluate concordance of T790M plasma mutation testing between the Cobas test and each of other platforms: Super-ARMS, digital PCR or NGS.
| percentage of aggrement | Experimental |
|---|---|
| For T790M, referred to Cobas, the concordance for Super-ARMS | 91.3 |
| For T790M, referred to Cobas, the concordance for 3D PCR | 66.8 |
| For T790M, referred to Cobas, the concordance for NGS | 82.7 |
| For T790M, referred to Cobas, the concordance for ddPCR | 86.1 |
| For T790M, referred to Super-ARMS, the concordance for 3D PCR | 71.0 |
| For T790M, referred to Super-ARMS, the concordance for NGS | 88.3 |
| For T790M, referred to Super-ARMS, the concordance for ddPCR | 88.1 |
| For T790M, referred to 3D PCR, the concordance for NGS | 76.5 |
| For T790M, referred to 3D PCR, the concordance for ddPCR | 72.2 |
| For T790M, referred to NGS, the concordance for ddPCR | 85.8 |
To assess the efficacy of AZD9291 monotherapy by assessment of PFS in adult patients with advanced or metastatic NSCLC, who have received prior EGFR- TKI therapy and are T790M mutation positive detected by any one of the four plasma testing platforms. PFS was defined using Response Evaluation Criteria In Solid Tumors version 1.1(RECIST v1.1).
| months | Experimental |
|---|---|
| As-treated Analysis Set (contained all patients who took at least one dose of AZD9291) | 9.7 (8.4 to 11.2) |
| T790M Positive in Plasma via Cobas at Baseline | 10.6 (8.5 to 13.8) |
| T790M Positive in Plasma via Super-ARMS at Baseline | 10.6 (8.7 to 12.5) |
| T790M Positive in Plasma via 3D PCR at Baseline | 9.7 (8.3 to 11.3) |
| T790M Positive in Plasma via NGS at Baseline | 11.0 (9.5 to 13.8) |
| T790M Positive in Plasma via ddPCR at Baseline | 10.5 (8.3 to 12.7) |
To evaluate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of Super-ARMS/digital PCR/NGS by using Cobas as the reference.
| percentage | Experimental |
|---|---|
| sensitivity for Super-ARMS | 94.7 |
| sensitivity for 3D PCR | 90.5 |
| sensitivity for NGS | 98.9 |
| sensitivity for ddPCR | 98.9 |
| specificity for Super-ARMS | 89.3 |
| specificity for 3D PCR | 52.5 |
| specificity for NGS | 73.0 |
| specificity for ddPCR | 78.5 |
| PPV for Super-ARMS | 84.1 |
| PPV for 3D PCR | 53.4 |
| PPV for NGS | 68.6 |
| PPV for ddPCR | 73.0 |
| NPV for Super-ARMS | 96.6 |
| NPV for 3D PCR | 90.2 |
| NPV for NGS | 99.1 |
| NPV for ddPCR | 99.2 |
To assess the efficacy of AZD9291 monotherapy by assessment of ORR in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. ORR is defined as the percentage of patients with measurable disease with at least 1 visit response of CR or PR. Data obtained until progression or last evaluable assessment in the absence of progression will be included in the assessment of ORR.
| percentage of participants | Experimental |
|---|---|
| As-treated Analysis Set | 56.3 (48.4 to 63.9) |
| T790M Positive in Plasma via Cobas at Baseline | 60.7 (49.7 to 70.9) |
| T790M Positive in Plasma via Super-ARMS at Baseline | 62.4 (52.2 to 71.8) |
| T790M Positive in Plasma via 3D PCR at Baseline | 54.1 (45.7 to 62.3) |
| T790M Positive in Plasma via NGS at Baseline | 62.0 (53.1 to 70.4) |
| T790M Positive in Plasma via ddPCR at Baseline | 59.1 (49.3 to 68.4) |
To assess the efficacy of AZD9291 monotherapy by assessment of overall survival (OS) in adult patients who have received prior EGFR-TKI therapy and are EGFR T790M mutation positive detected by any one of the four plasma testing platforms. 75% OS duration was calculated.
| months | Experimental |
|---|---|
| As-treated Analysis Set | 9.7 (7.5 to 12.7) |
| T790M Positive in Plasma via Cobas at Baseline | 10.5 (7.3 to 13.6) |
| T790M Positive in Plasma via Super-ARMS at Baseline | 10.7 (8.0 to 14.5) |
| T790M Positive in Plasma via 3D PCR at Baseline | 8.7 (7.3 to 12.1) |
| T790M Positive in Plasma via NGS at Baseline | 11.9 (8.7 to 15.3) |
| T790M Positive in Plasma via ddPCR at Baseline | 10.6 (8.0 to 14.3) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental | — | — | — |
| Age, Continuous(years) | Experimental |
|---|---|
| Mean | 58.54 ± 9.506 |
| Sex: Female, Male(Participants) | Experimental |
|---|---|
| Female | 160 |
| Male | 96 |
| Race (NIH/OMB)(Participants) | Experimental |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 256 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| enrollment number(Participants) | Experimental |
|---|---|
| Patients who have progressed following prior therapy with an EGFR-TKI agent. | 256 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Dec 2016 to primary completion in Oct 2018, 22 months.
Results were first posted in Mar 2024, 5 years 4 months after primary completion. A results delay was requested in Sep 2019.
Of 62 industry-sponsored phase 3 interventional studies under Lung Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 44. This study's 22 months is below that.
Counting every sponsor, half of 128 studies reached it within 44 months; a quarter within 30 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib